Optimization of allogeneic transplant conditioning: not the time for dogma (Q36556498)

14 August 2017

1 reference

title

Optimization of allogeneic transplant conditioning: not the time for dogma (English)

1 reference

14 August 2017

1

H J Deeg

1 reference

14 August 2017

M B Maris

2

1 reference

14 August 2017

B L Scott

series ordinal

3

1 reference

14 August 2017

E H Warren

series ordinal

4

1 reference

14 August 2017

publication date

3 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1701-1705

1 reference

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Molecules and mechanisms of the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Adoptive transfer of allogeneic antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Protective conditioning for acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404327

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404327

1 reference

14 August 2017

1 reference